Deutsche Bank Ag\ Chinook Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$18.66 - $38.58 $3.45 Million - $7.14 Million	185,078 Added 343.76%	238,918 $9.18 Million
Q1 2023 May 15, 2023	BUY	$21.53 - $26.8 $680,563 - $847,148	31,610 Added 142.2%	53,840 $1.25 Million
Q4 2022 Feb 13, 2023	BUY	$18.63 - $27.35 $25,020 - $36,731	1,343 Added 6.43%	22,230 $582,000
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $4,114 - $5,491	235 Added 1.14%	20,887 $411,000
Q2 2022 Aug 11, 2022	SELL	$12.59 - $18.8 $7,629 - $11,392	-606 Reduced 2.85%	20,652 $361,000
Q1 2022 May 13, 2022	SELL	$12.02 - $16.69 $29,905 - $41,524	-2,488 Reduced 10.48%	21,258 $348,000
Q4 2021 Feb 11, 2022	BUY	$10.69 - $16.83 $50,264 - $79,134	4,702 Added 24.69%	23,746 $387,000
Q3 2021 Nov 04, 2021	BUY	$11.5 - $14.86 $4,289 - $5,542	373 Added 2.0%	19,044 $243,000
Q2 2021 Aug 11, 2021	BUY	$13.6 - $18.98 $132,069 - $184,314	9,711 Added 108.38%	18,671 $264,000
Q1 2021 May 13, 2021	SELL	$14.17 - $19.11 $11,931 - $16,090	-842 Reduced 8.59%	8,960 $139,000
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $116,643 - $204,959	9,802 New	9,802 $155,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.